References
- Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1): 1–47. doi: 10.1111/j.1365-2516.2012.02909.x.
- Sulser E. A patient's perspective on hemophilia. Semin Hematol 2006; 43(2 Suppl 3): S13–6. doi: 10.1053/j.seminhematol.2006.02.005.
- Jansen MO, Angelos P, Schrantz SJ, Donington JS, Madariaga MLL, Zakrison TL. Fair and equitable subject selection in concurrent COVID-19 clinical trials. J Med Ethics 2021; 47(1): 7–11. doi: 10.1136/medethics-2020-106590.
- Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 5th edn. 2001. New York: Oxford University Press.
- Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 2016; 35: 185–198. doi: 10.1200/EDBK_156686.
- Dobra R, Scott S, Davies JC, Simmonds NJ. Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials. J Cyst Fibros 2019; 18(5): e45–e46. doi: 10.1016/j.jcf.2019.04.008.
- Weijer C. Selecting subjects for participation in clinical research: one sphere of justice. J Med Ethics 1999; 25(1): 31–36. doi: 10.1136/jme.25.1.31.
- MacKay D, Saylor KW. Four faces of fair subject selection. Am J Bioeth 2020; 20(2): 5–19. doi: 10.1080/15265161.2019.1701731.
- Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000; 283(20): 2701–2711. doi: 10.1001/jama.283.20.2701.
- Strassle C. Fair subject selection in cystic fibrosis trials. J Cyst Fibros 2019; 18(5): e47. doi: 10.1016/j.jcf.2019.05.019.
- MacKay D. Fair subject selection in clinical research: formal equality of opportunity. J Med Ethics 2016; 42(10): 672–677. doi: 10.1136/medethics-2015-103311.
- Gupta R, Morain SR. Ethical allocation of future COVID-19 vaccines. J Med Ethics 2020 Dec 17:medethics-2020-106850. doi: 10.1136/medethics-2020-106850. Epub ahead of print.
- Henn W. Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity. Vaccine 2020;38(34):5396–5397. doi:10.1016/j.vaccine.2020.06.058.
- Rawlings A, Brandt L, Ferreres A, et al. Ethical considerations for allocation of scarce resources and alterations in surgical care during a pandemic. Surg Endosc 2021; 35(5): 2217–2222. doi: 10.1007/s00464-020-07629-x.
- Guidolin K, Catton J, Rubin B, et al. Ethical decision making during a healthcare crisis: a resource allocation framework and tool. J Med Ethics 2021; medethics-2021-107255. doi: 10.1136/medethics-2021-107255.
- Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.TCPS 2. December 2018. Ottawa, ON: Secretariat on Responsible Conduct of Research. Available from
https://ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2018.html (accessed 27 July 2021). - Wells JR, Gater A, Marshall C, Tritton T, Vashi P, Kessabi S. Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94-9027 extension studies (PROTECT VIII). Patient 2019; 12(6): 611–619. doi: 10.1007/s40271-019-00374-x.
- Iorio A, Marchesini E, Marcucci M, et al. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; (9): CD003429. doi: 10.1002/14651858.CD003429.pub4.
- Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: Defining patient important outcomes. Res Pract Thromb Haemost 2019; 3(2): 184–192. doi: 10.1002/rth2.12195.
- Zhou ZY, Riske B, Forsberg AD, et al. Self-reported barriers to hemophilia care in people with factor VIII deficiency. Am J Prev Med 2011; 41(6 Suppl 4): S346–S353. doi:10.1016/j.amepre.2011.09.003.
- Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013 May 16; 4: 49–56. doi: 10.2147/JBM.S43734.
- Soares BMD, Simeoni LA, de Almeida KJQ, et al. Factors associated with compliance with the treatment protocol and mortality in adults with hemophilia. Patient Prefer Adherence 2020; 14: 2279–2285. doi:10.2147/PPA.S279401.
- Bodicoat DH, Routen AC, Willis A, et al. Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action. Trials 2021;22(1):880. doi:10.1186/s13063-021-05849-7.